[I assume, in particular, that ARRY will be discussing the biomarker they have identified for ARRY-520. Not sure if there will be a lot of new meaningful info on ARRY-614.]
Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
BOULDER, Colo., Nov. 1, 2012 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will hold a conference call on Monday, November 5, 2012 at 4:30 p.m. Eastern Time to discuss submitted 2012 American Society of Hematology Annual Meeting abstracts on ARRY-520, a KSP inhibitor for multiple myeloma and ARRY-614, a dual p38/Tie2 inhibitor for myelodysplastic syndromes. Ron Squarer, Chief Executive Officer and Kevin Koch, Ph.D., President and Chief Scientific Officer, will lead the call.
A replay of the call will be available as a webcast on www.arraybiopharma.com
About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. For more information on Array, please go to www.arraybiopharma.com.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.